The Case for Deployable Respiratory Protection

The Case for Deployable Respiratory Protection

The Preparedness Problem

Respiratory virus preparedness has historically been understood as a government and institutional challenge. Stockpile antivirals. Develop vaccines. Build surge capacity. These are necessary measures, and the infrastructure built around them has demonstrable value.

But there is a dimension of preparedness that this infrastructure does not address: the window between the emergence of a respiratory threat and the availability of a pathogen-specific response. Vaccine development takes months. Distribution takes additional time. During that period, populations remain exposed, and the tools available to act are limited.

An effective preparedness strategy requires interventions that are deployable before a specific pathogen is characterized, and accessible without the clinical infrastructure that many pathogen-specific tools depend on.

Deployability as a Design Requirement

Deployability is not a secondary feature. It is a design requirement for any intervention intended to function in a preparedness context.

An intervention that requires cold chain logistics, clinical administration, or prior diagnosis cannot be deployed rapidly at scale during the early phase of an outbreak. These constraints do not reflect failures of existing tools. They reflect the design requirements of pathogen-specific approaches, which by necessity involve complex manufacturing, distribution, and administration systems.

A host-directed, self-administered prophylactic operates under different constraints. It does not require a specific pathogen to be identified in advance. It does not require a clinical setting to administer. It can be deployed across populations and geographies at the speed the situation demands, whether that is a seasonal respiratory period, a healthcare outbreak, or a broader preparedness context.

N001 and the Deployability Rationale

N001, Ness Therapeutics Inc.'s lead program, is designed with these requirements in mind. As a self-administered intranasal prophylactic, it requires no injection and no clinical visit. Because it activates the host's own innate antiviral defences rather than targeting a specific pathogen, its relevance is not contingent on which virus is circulating.

This positions N001 as relevant across a broad range of settings: seasonal respiratory infections, healthcare and frontline environments, outbreak response, and preparedness contexts where the speed of deployment is as important as the intervention itself.

N001 is currently in IND/CTA-enabling development, supported by funding from the Government of Canada and in partnership with the National Research Council of Canada, advancing toward first-in-human readiness.

To follow the program's progress or explore investment opportunities, visit www.nesstherapeuticsinc.com/contact-us.